The endometrial ablation market is expected to generate US$ 3.4 billion in sales in 2023 and grow at a compound annual growth rate (CAGR) of 7.3% from 2023 to 2033, according to a recently released Future Market Insights research. The market is expected to reach US$ 6.8 billion by the end of 2033. In 2022, the combined GDP of the US and China was US$ 1.4 billion.

Endometrial ablation is a medical procedure designed to treat abnormal uterine bleeding by removing or destroying the lining of the uterus, known as the endometrium. This technique is often considered for women who experience heavy menstrual bleeding (menorrhagia) that doesn’t respond well to other treatments like medications. By targeting the endometrial lining, the procedure aims to reduce or eliminate menstrual bleeding, offering relief to those who suffer from this debilitating condition.

Unleash the extraordinary. Claim your sample for unmatched efficiency:
https://www.futuremarketinsights.com/reports/sample/rep-gb-16577

The endometrial ablation procedure is minimally invasive, and it is usually performed on an outpatient basis. It offers several advantages compared to more invasive surgical options like hysterectomy. Some benefits of endometrial ablation include shorter recovery times, lower risks of complications, and the preservation of the uterus. This is particularly important for women who still wish to have children in the future.

With the advent of minimally invasive endometrial ablation treatments, the endometrium can be destroyed in a more expedient, outpatient setting. This operation is less dangerous and technically straightforward to carry out.

The International Federation of Gynaecology and Obstetrics estimates that between 3% and 30% of reproductive-aged women are affected by ABillionormal Uterine Bleeding. Women’s treatment plans have become the key focus of the general health industry in the modern world. Governments and private organizations around the world have placed women’s health at the center of their wellbeing race.

In India, such as in many other locations, women are eligible for several tax benefits and exemptions under the provisions of several sections of the tax code. Women’s healthcare initiatives may promote the effectiveness of treatment alternatives, which will boost the market.

Key players:

• Medtronic
• CooperSurgical Inc.
• Boston Scientific Corp.
• Ethicon, Inc.
• Olympus Corp.
• Richard Wolf GmbH
• AngioDynamics
• Hologic, Inc.
• Minerva Surgical, Inc.

A few of the recent developments in the market are:

• In February 2021, CooperSurgical, a division of CooperCompanies, acquired Aegea Medical, nearly a year after the company received FDA approval for its Mara water vapor ablation system for severe menstrual bleeding.
• In May 2019, Medtronic Plc announced a partnership with Koninklijke Philips N.V. This collaboration is projected to result in an integrated cryoablation solution that is cutting-edge in terms of image guidance.
• In April 2021, Olympus Corporation relocated its Therapeutic Solutions Division’s worldwide headquarters from Tokyo to the United States in order to gain better access to the medical industry and earn more revenue through expanded commercial prospects.
• In June 2021, Boston Scientific purchased the remaining shares of FARAPULSE. Boston Scientific’s electrophysiology sector was bolstered by the acquisition, which added pulsed-field ablation technology to the company’s offerings.

Key Segments:

By Type:

• Devices
• Cryoablation
• Radiofrequency Ablation
• Hydrothermal Ablation
• Thermal Balloon
• Microwave Energy
• Procedures

By End User:

• Hospitals
• Clinics
• Ambulatory Surgery Centers